Pharma Stocks Experience Sustained Rally, Up to 27% in a Month: Can Industry Shield Portfolios from Global Market Volatility?

Pharma Stocks Defy Broader Market Weakness Amid Geopolitical Tensions

The Indian pharmaceutical sector has staged a strong rally this year, outperforming the broader market despite rising geopolitical tensions stemming from the US-Iran war in the Middle East. The Nifty Pharma index has surged nearly 11% over the past month, significantly outperforming the Nifty 50, which declined 3.6% during the same period.

On a year-to-date basis, the Nifty Pharma index has gained 9.4%, while the benchmark Nifty 50 has fallen by an equal margin. The pharma sector has also outperformed most peers, many of which remain under pressure due to global headwinds, elevated energy prices, and subdued earnings growth.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

Gland Pharma Leads the Charge

All stocks in the Nifty Pharma index posted positive returns over the past month, with Gland Pharma emerging as the top performer, rallying over 27%. Laurus Labs and Biocon followed closely, gaining 21-23%. Shares of Ajanta Pharma, Cipla, Mankind Pharma, Granules India, Sun Pharmaceutical Industries, Zydus Lifesciences, and JB Chemicals & Pharmaceuticals advanced between 10% and 15%. Torrent Pharmaceuticals, Divi’s Laboratories, Dr Reddy’s Laboratories, Abbott India, Ipca Laboratories, Aurobindo Pharma, Natco Pharma, and Glenmark Pharmaceuticals shares rose between 6% and 10%. The only laggards in the Nifty Pharma index were Lupin, whose shares declined 0.57%, and Alkem Laboratories, which fell 2.91%.

Stronger Earnings and Currency Movement Drive Rally

The recent rally in pharma stocks has been driven by a combination of stronger-than-expected quarterly earnings, rupee depreciation, and an improving business outlook across companies. Dr. Ravi Singh, Chief Research Officer at Master Capital Services, attributes the rise to better-than-expected quarterly numbers, a weaker rupee, and improving business prospects across pharmaceutical companies. Maitri Sheth, Pharma Analyst at Choice Institutional Equities, notes that pharmaceutical companies have reported better-than-expected Q4 and FY26 performance in both revenue and margins, aided by specialty launches, an improving chronic portfolio mix, and sustained demand trends.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

Pharma Stocks as a Defensive Play

Pharma stocks have historically been viewed as a defensive play during periods of uncertainty, given that healthcare demand tends to remain stable irrespective of economic cycles or geopolitical disruptions. However, Dr. Singh cautions investors against viewing pharma as a complete hedge against market corrections. He notes that while pharma can help reduce portfolio volatility and provide stability during uncertain periods, no sector is entirely insulated from broad market pressures.